Trial Profile
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms DAYBREAK
- Sponsors Celgene Corporation; Receptos
- 29 Feb 2024 According to a Bristol-Myers Squibb media release, long-term disability progression in ozanimod-treated participants with relapsing multiple sclerosis from the SUNBEAM, RADIANCE, and DAYBREAK trials will be presented at the 9th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 in West Palm Beach, Florida taking place February 29 to March 2.
- 29 Feb 2024 According to a Bristol-Myers Squibb Media Release, data will be presented at the 9th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 in West Palm Beach, Florida taking place February 29 to March 2.
- 29 Feb 2024 Results presented in a Bristol-Myers Squibb Media Release.